Vitexicarpin Acts as a Novel Angiogenesis Inhibitor and Its Target Network

Figure 5

Vitexicarpin inhibits VEGF-induced angiogenesis ex vivo and in vivo. (a) Vitexicarpin inhibits VEGF-induced angiogenesis in the CAM assay in vivo. In comparison to DMSO group, the application of VEGF (10 ng/mL) induced a strong vascularization. In contrast, the simultaneous application of VEGF and vitexicarpin blocked VEGF-induced angiogenesis. ^∗∗𝑃<0.01; ^∗∗∗𝑃<0.001 compared with VEGF group; bars, ± SD. (b) H&E staining (upper panels) and anti-CD31 stained blood vessels (lower panels) of tumor sections from NS and vitexicarpin (150 mg/kg). Vitexicarpin inhibits tumor angiogenesis in allograft mouse tumor model. All images, ×200 magnification.^∗∗∗𝑃<0.001 compared with NS group; Error bars, ± SD.

(a)

(b)